ACET
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
Adicet Bio, Inc. (ACET) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D-). The rating has held at C for 4 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B+ (3.7) | C (2.5) | D+ (1.6) | D- (1.0) | C+ (2.6) | C (2.3) |
| 2026-11-10 | B+ (3.8) | C+ (2.6) | D+ (1.6) | D (1.2) | C+ (2.6) | C (2.4) |
| 2026-11-03 | B+ (3.7) | C (2.5) | D+ (1.6) | D (1.2) | C+ (2.7) | C (2.3) |
| 2026-10-27 | B+ (3.7) | C (2.4) | D+ (1.7) | C- (1.9) | C+ (2.6) | C (2.5) |
| 2026-10-20 | B+ (3.7) | C (2.4) | D+ (1.6) | D+ (1.8) | C+ (2.6) | C (2.4) |